Drug intelligence / Profile preview

FP-004

Development stage: Unknown
Lead developer: Foresee Pharmaceuticals
Modality: Small Molecules
Administration: Subcutaneous

Overview

**FP-004** is a novel, subcutaneously injectable formulation of **buprenorphine**, an opioid receptor agonist developed by Foresee Pharmaceuticals. It leverages the company's stabilized injectable formulation (SIF) depot delivery platform to provide sustained release for potential use in pain management or opioid use disorder treatment. Currently in the preclinical stage, FP-004 is available for partnering and represents part of Foresee's portfolio of improved injectable therapies targeting specialty markets with unmet needs.[1][3][5]

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on FP-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FP-004.

Explore the full profile